An interventional study of intermittent theta burst stimulation (iTBS) intervention in Major Depression Disorder, Cognitive Deficits and Selective Attention, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cognition Disorders with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Cognition Disorders · China.
Among the 23 studies in Cognition Disorders with a site in China, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 19th registered.
399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.
Browse Cognition Disorders studies →11 of the 23 studies in Cognition Disorders with a site in China are open now. Recruiting first, the newest first:
Westlake University · Sites in China
Ages 55–90 · Healthy volunteers
Yuju Wu · Sites in China
Ages 60–79 · Healthy volunteers
Zhejiang University · Sites in China
Ages 60–80 · Healthy volunteers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 60–85 · Healthy volunteers
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 40–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 66 across 272 interventional studies indexed under Cognition Disorders.
Median enrollment 94 across the 15 interventional studies, 221 across the 8 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 10 most frequent:
University of Electronic Science and Technology of China is the lead sponsor of 112 studies on the registry; 37 are open to participants now.
University of Electronic Science and Technology of China has 1 study filed under Cognition Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Cognition Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07573475Ke Dong, MDThe Effect of tDCS Combined With TMS on Cognitive Impairment and Motor Function After Stroke | 2027-05-01 |
| NCT07573501Ke Dong, MDDual-site Cross-frequency Coupled Transcranial Electrical Stimulation Modulates Working Memory of Patients With Post-stroke Cognitive Impairment | 2027-05-01 |
| NCT06904092Shanghai Mental Health CenterEfficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Cognition Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multimodal study (Behavior, TMS, EEG) combining a sham-controlled intermittent theta burst stimulation (iTBS) intervention with an additional-singleton task and EEG to evaluate whether left dorsolateral prefrontal cortex (DLPFC) stimulation enhances cognitive control and modulates maladaptive attention processes in MDD and whether the effects are influenced by neuronavigated versus manual (Beam F3 method) localization of the stimulation site.
Major Depressive Disorder (MDD) is associated with impaired selective attention and disrupted top-down control, yet the underlying neurophysiological mechanisms remain poorly understood. The present double-blind, sham-controlled trial will test whether iTBS over the left DLPFC, an FDA-approved rTMS site, can restore top-down distractor suppression in MDD (active-iTBS: n = 30; sham-iTBS: n = 30). Neuronavigated iTBS will be delivered across sessions, and effects will be assessed on the behavioral level (additional singleton paradigm) and the neurophysiological level (using concomitant EEG). Key aim of the project is to compare neuronavigated (active-iTBS) versus manual (Beam F3 method, sham-iTBS group) localization of the stimulation site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neuronavigation procedure: During the iTBS treatment, the high-resolution T1-weighted scans of each subject will be uploaded to the BrainSight neuronavigation system (version 2.4.11), adjusted, and remodelled into a three-dimensional model. Then, the neuronavigation system is calibrated and validated on the subject. Next, we localized each participant's left-lateral dlPFC stimulation target using Talairach coordinates (-45, 45, 35). The head position is standardized using the nasal tip, sinuses, and bilateral ear screens as baseline markers, and the location of the target on the scalp is identified in each participant's natural space anatomical image. In the end, we observe on the computer screen whether the coil position is placed above the target through the navigation software and artificially control the coil to be tangent to the skull, with the center of the figure-of-eight coil always directly above the target.
Device: intermittent theta burst stimulation (iTBS) intervention
Target Localization and Cap Placement Procedure: The stimulation target was the EEG 10-20 coordinate F3, corresponding to the probabilistic location of the left dorsolateral prefrontal cortex (DLPFC). We localized this site using the Beam F3 method and a TMS elastic cap (patent no. 201120150878.5, Wuhan YIRUIDE Medical Equipment Co., Ltd.), and verified it with the F3 electrode on the standard EEG cap. Before the first session, the elastic cap was aligned using anatomical landmarks (nasion, inion, and ears), and the F3 position was marked for consistent coil placement. This standardized approach ensured precise and repeatable targeting across TMS sessions.
Device: intermittent theta burst stimulation (iTBS) intervention
iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.
Depression severity following two weeks of iTBS treatment.
Depression severity will be assessed, using 24-item Hamilton Depression Scale (HAMD-24) before and after the iTBS intervention. Changes will be computed as (pre-treatment score - post-treatment score)/pre-treatment score × 100%). We hypothesize that the neuronaviogated group has a better treatment effect indexed by the mean HAMD subtraction rate than the sham-control group.
Time frame: 60-90 minutes before the first iTBS treatment and 60-90 minutes after last iTBS treatment.
Intervention-related ERPs changes in the additional singleton task after 2 weeks of active/sham iTBS treatment.
Neuromodulation-induced iTBS changes will be measured by the probability cueing effects in the additional singleton task with ERP effects. N2pc and Pd components will be used to quantify attentional selection and distractor suppression. These ERP components reflect the neural mechanisms of spatial attention in MDD.
Time frame: 30-60 minutes before the first iTBS treatment and 30-60 minutes after last iTBS treatment.
Intervention-related brain connectivity after 2 weeks of active/sham iTBS treatment.
During the additional singleton task, we will measure network-level connectivity patterns between attention-related brain regions (e.g., fronto-parietal and sensory integration systems). Directed or undirected EEG connectivity methods (e.g., phase synchronization, Granger causality, or sPDC) will be applied to assess iTBS-induced changes in intrinsic attentional network architecture in MDD.
Time frame: 30-60 minutes before the first iTBS treatment and 30-60 minutes after last iTBS treatment.
Intervention-related behavior changes in the additional singleton task after 2 weeks of active/sham iTBS treatment.
Neuromodulation-induced iTBS changes will also be measured in RTs. We aim to examine whether the different RT effects in both groups occur between the pre-iTBS and post-iTBS conditions. For the between-group effect, compared to the sham-iTBS group, the active-iTBS group has faster RTs and statistical learning effects (e.g., subtraction RTs from the low-minus-high-probability distractor locations).
Time frame: 30-60 minutes before the first iTBS treatment and 30-60 minutes after the last iTBS treatment.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2028, 59 months after the start.
Of 88 non-industry interventional studies with no phase under Cognition Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 55. This study's planned 59 months is above that.
Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 16 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Electronic Science and Technology of China →